▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / VCNX

VCNX — VACCINEX, INC.

—
OTC · Health Care · Pharmaceuticals · CIK 1205922 ·
Last close
$1.00
Market Cap
$2.68M
52W High
$1.50
52W Low
$0.34
ADV30
2,040
Next earnings
—
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2024 213,000 — -3,387,000 -3,374,000 2,596,000 1,107,000 5,084,000
Sep 2024 52,000 — -4,552,000 -5,732,000 4,854,000 2,906,000 6,175,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,139,000
Investing CF
$-8,000
Financing CF
$8,021,000
CapEx
$-8,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.83
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-358,561,000
Inventory
—
Receivables
$838,000
ST Investments
—
EBIT TTM
$-9,104,000
Pretax Income TTM
$-9,106,000
Interest Exp TTM
$2,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$601,000
EBITDA
$-18,641,000
Free Cash Flow
$-11,543,625
Enterprise Value
$3,259,637
Total Cash
$1,107,000
Total Debt
$25,000
Shares Out
2,676,637
Trailing EPS
$-8.88
Book Value
$-1.55
ROE
—
ROA
-376.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 601,000 -18,735,000 -18,634,000 2,596,000 5,084,000 — -16,186,000
Dec 2023 570,000 -22,885,000 -20,251,000 3,631,000 5,942,000 — -21,379,000
Dec 2022 275,000 -19,906,000 -19,815,000 7,977,000 2,784,000 — -19,074,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.14

Peers — same industry

TickerNameMarket CapLastDaily %
OGEN ORAGENICS INC $2.67M $0.59 —
LIFD LFTD PARTNERS INC. $2.67M $0.18 —
PPBT PURPLE BIOTECH LTD. $2.70M $2.90 —
CMND Clearmind Medicine Inc. $2.64M $2.59 —
PKTX ProtoKinetix, Inc. $2.60M $0.01 —

News headlines (Yahoo Finance, 1h cache)

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
2025-12-23 13:01 · Yahoo
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
2025-05-27 12:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →